SHARE
Artemisinin Combination Therapy Market

Artemisinin Combination Therapy Market Forecasts to 2028 – Global Analysis By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine, Artesunate+Mefloquine) and By Geography

4.9 (68 reviews)
Published: November 2021 ID: SMRC21178
4.9 (68 reviews)
Published: November 2021 ID: SMRC21178

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Artemisinin Combination Therapy Market is accounted for $473.24 million in 2020 and is expected to reach $1,051.92 million by 2028 growing at a CAGR of 10.5% during the forecast period. Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are major factors driving the growth of the market. However, limited number of manufacturers globally is hampering the market.

Artemisinin is a plant derivative isolated from Artemisia annua, or sweet wormwood, which is known to effectively and swiftly reduce the number of plasmodium parasites in the blood of malaria patients. Artemisinin combination therapy is rapid and reliably effective in treating uncomplicated malaria. The artemisinin derivatives are safe and well tolerated except for occasional hypersensitivity reactions. The adverse effect of the artemisinin combination therapy is based and determined by the combined drug.

By type, Artesunate–Mefloquine segment is experiencing considerable market growth, due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.

Based on the geography, Middle East & Africa is dominating the market during the forecast period, owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.

Some of the key players profiled in the Artemisinin Combination Therapy Market include Cipla Ltd., Desano Inc., Hovid Berhad, KPC Pharmaceuticals, Guilin Pharmaceutical (Fosun Pharmaceutical ), Novartis AG, Sanofi S.A.

Types Covered:
• Artemether+Lumefantrine
• Artesunate+Amodiaquine
• Artesunate+Mefloquine
• Artesunate+Sulfadoxine-Pyrimethamine
• Dihydroartemisinin+Piperaquine
• Pyronaridine-Artesunate    
    
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Select License Type

NEW YEAR SALE
Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials